Last reviewed · How we verify
Placebo comparator - no ceftriaxone
This is a placebo control arm with no active antibiotic intervention, used as a comparator in a clinical trial.
At a glance
| Generic name | Placebo comparator - no ceftriaxone |
|---|---|
| Sponsor | The George Institute |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
In this Phase 3 trial design, the placebo comparator group receives no ceftriaxone (a third-generation cephalosporin antibiotic) to establish a baseline for efficacy and safety comparison against the active treatment arm. This allows researchers to measure the true clinical benefit of ceftriaxone administration in the studied patient population.
Approved indications
Common side effects
Key clinical trials
- PRophylaxis Against Early VENTilator-associated Infections in Acute Brain Injury (PHASE3)
- Antimicrobial Treatment in Patients With Ventilator-associated Tracheobronchitis (PHASE4)
- Ceftriaxone to PRevent pneumOnia and inflammatTion aftEr Cardiac arresT (PROTECT) (PHASE2)
- New AntiBiotic Treatment Options for Uncomplicated Anogenital GOnorrhoea (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo comparator - no ceftriaxone CI brief — competitive landscape report
- Placebo comparator - no ceftriaxone updates RSS · CI watch RSS
- The George Institute portfolio CI